A vérkoleszterinszint-csökkentésének új lehetosége - A koleszterinfelszívódás és szintézis együttes gátlásának klinikai jelentosége

Translated title of the contribution: New treatment option for decreasing blood cholesterol level - Clinical importance of dual inhibition of cholesterol-absorption and synthesis

G. Paragh, Lászlo Márk, Zsigmond Czine

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

In the development of hypercholesterinaemia two factors play an important role. There is the cholesterol-uptake through the gastrointestinal tract, about 300-700 mg daily depending on the diet, on the other hand gastrointestinal tract plays important role in the reabsorption of cholesterol excreted through the bile by the liver, the amount of which takes 1000 mg. It means that about 1300-1700 mg cholesterol is absorbed in the small intestine daily. Previous major studies have demonstrated that statins, the drugs that have been proved to be the most efficient in decreasing the cholesterol level, can decrease both total and cardiovascular mortality. This effect highly depends on the rate of cholesterol level decrease. Thus, their application in higher doses has been recently suggested to reach the target level, which is performed by dose titration. If the desired effect is not achieved with the starting dose of statins, a doubling of dosage only leads to 6% additional LDL-cholesterol level decrease. During long term administration the so called "escape phenomenon" can be observed, which means that the use of these drugs for a longer period reduces their cholesterol decreasing effect. Higher doses increase the risk of adverse effects, and the "escape phenomenon" decreases the effectiveness. To avoid these effects the combination therapy is recommended for use. In combination therapy drugs with different mechanisms of action should be administered, which increase therapeutic effect, but keep the number of adverse effects decreased or unchanged. Concomitant administration of former known lipid lowering agents - beyond enhancing cholesterol level decrease - has unfortunately increased the frequency of adverse effects as well. In this regard, ezetemibe, the cholesterol absorption inhibitor appears to be promising since it selectively decreases the absorption of cholesterol from intestinal epithelial cell, resulting in an 18-22% LDL-cholesterol decrease. At the same time the decreased uptake from the gastrointestinal tract triggers the endogen cholesterol synthesis in the liver. When this process is inhibited by statin, more impressive cholesterol decreasing effect can be reached. Clinical studies with concurrent use of ezetimibe and statin have confirmed this view. Decreasing cholesterol level at more attack points offers a possibility to reach target values without a significant increase in the risk of adverse effects. So with combination and dual inhibition a more significant cholesterol lowering effect can be obtained beside the decrease of side effects.

Original languageHungarian
Pages (from-to)805-811
Number of pages7
JournalOrvosi Hetilap
Volume145
Issue number15
Publication statusPublished - Apr 2004

Fingerprint

Cholesterol
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Therapeutics
Gastrointestinal Tract
LDL Cholesterol
Anticholesteremic Agents
Liver
Intestinal Absorption
Therapeutic Uses
Combination Drug Therapy
Bile
Pharmaceutical Preparations
Small Intestine
Epithelial Cells
Diet
Lipids
Mortality

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A vérkoleszterinszint-csökkentésének új lehetosége - A koleszterinfelszívódás és szintézis együttes gátlásának klinikai jelentosége. / Paragh, G.; Márk, Lászlo; Czine, Zsigmond.

In: Orvosi Hetilap, Vol. 145, No. 15, 04.2004, p. 805-811.

Research output: Contribution to journalArticle

@article{462763545f0d4fceb7f3aa2d99b7c9b2,
title = "A v{\'e}rkoleszterinszint-cs{\"o}kkent{\'e}s{\'e}nek {\'u}j lehetos{\'e}ge - A koleszterinfelsz{\'i}v{\'o}d{\'a}s {\'e}s szint{\'e}zis egy{\"u}ttes g{\'a}tl{\'a}s{\'a}nak klinikai jelentos{\'e}ge",
abstract = "In the development of hypercholesterinaemia two factors play an important role. There is the cholesterol-uptake through the gastrointestinal tract, about 300-700 mg daily depending on the diet, on the other hand gastrointestinal tract plays important role in the reabsorption of cholesterol excreted through the bile by the liver, the amount of which takes 1000 mg. It means that about 1300-1700 mg cholesterol is absorbed in the small intestine daily. Previous major studies have demonstrated that statins, the drugs that have been proved to be the most efficient in decreasing the cholesterol level, can decrease both total and cardiovascular mortality. This effect highly depends on the rate of cholesterol level decrease. Thus, their application in higher doses has been recently suggested to reach the target level, which is performed by dose titration. If the desired effect is not achieved with the starting dose of statins, a doubling of dosage only leads to 6{\%} additional LDL-cholesterol level decrease. During long term administration the so called {"}escape phenomenon{"} can be observed, which means that the use of these drugs for a longer period reduces their cholesterol decreasing effect. Higher doses increase the risk of adverse effects, and the {"}escape phenomenon{"} decreases the effectiveness. To avoid these effects the combination therapy is recommended for use. In combination therapy drugs with different mechanisms of action should be administered, which increase therapeutic effect, but keep the number of adverse effects decreased or unchanged. Concomitant administration of former known lipid lowering agents - beyond enhancing cholesterol level decrease - has unfortunately increased the frequency of adverse effects as well. In this regard, ezetemibe, the cholesterol absorption inhibitor appears to be promising since it selectively decreases the absorption of cholesterol from intestinal epithelial cell, resulting in an 18-22{\%} LDL-cholesterol decrease. At the same time the decreased uptake from the gastrointestinal tract triggers the endogen cholesterol synthesis in the liver. When this process is inhibited by statin, more impressive cholesterol decreasing effect can be reached. Clinical studies with concurrent use of ezetimibe and statin have confirmed this view. Decreasing cholesterol level at more attack points offers a possibility to reach target values without a significant increase in the risk of adverse effects. So with combination and dual inhibition a more significant cholesterol lowering effect can be obtained beside the decrease of side effects.",
keywords = "Cholesterol, Combination therapy, Ezetimibe, Statin",
author = "G. Paragh and L{\'a}szlo M{\'a}rk and Zsigmond Czine",
year = "2004",
month = "4",
language = "Hungarian",
volume = "145",
pages = "805--811",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "15",

}

TY - JOUR

T1 - A vérkoleszterinszint-csökkentésének új lehetosége - A koleszterinfelszívódás és szintézis együttes gátlásának klinikai jelentosége

AU - Paragh, G.

AU - Márk, Lászlo

AU - Czine, Zsigmond

PY - 2004/4

Y1 - 2004/4

N2 - In the development of hypercholesterinaemia two factors play an important role. There is the cholesterol-uptake through the gastrointestinal tract, about 300-700 mg daily depending on the diet, on the other hand gastrointestinal tract plays important role in the reabsorption of cholesterol excreted through the bile by the liver, the amount of which takes 1000 mg. It means that about 1300-1700 mg cholesterol is absorbed in the small intestine daily. Previous major studies have demonstrated that statins, the drugs that have been proved to be the most efficient in decreasing the cholesterol level, can decrease both total and cardiovascular mortality. This effect highly depends on the rate of cholesterol level decrease. Thus, their application in higher doses has been recently suggested to reach the target level, which is performed by dose titration. If the desired effect is not achieved with the starting dose of statins, a doubling of dosage only leads to 6% additional LDL-cholesterol level decrease. During long term administration the so called "escape phenomenon" can be observed, which means that the use of these drugs for a longer period reduces their cholesterol decreasing effect. Higher doses increase the risk of adverse effects, and the "escape phenomenon" decreases the effectiveness. To avoid these effects the combination therapy is recommended for use. In combination therapy drugs with different mechanisms of action should be administered, which increase therapeutic effect, but keep the number of adverse effects decreased or unchanged. Concomitant administration of former known lipid lowering agents - beyond enhancing cholesterol level decrease - has unfortunately increased the frequency of adverse effects as well. In this regard, ezetemibe, the cholesterol absorption inhibitor appears to be promising since it selectively decreases the absorption of cholesterol from intestinal epithelial cell, resulting in an 18-22% LDL-cholesterol decrease. At the same time the decreased uptake from the gastrointestinal tract triggers the endogen cholesterol synthesis in the liver. When this process is inhibited by statin, more impressive cholesterol decreasing effect can be reached. Clinical studies with concurrent use of ezetimibe and statin have confirmed this view. Decreasing cholesterol level at more attack points offers a possibility to reach target values without a significant increase in the risk of adverse effects. So with combination and dual inhibition a more significant cholesterol lowering effect can be obtained beside the decrease of side effects.

AB - In the development of hypercholesterinaemia two factors play an important role. There is the cholesterol-uptake through the gastrointestinal tract, about 300-700 mg daily depending on the diet, on the other hand gastrointestinal tract plays important role in the reabsorption of cholesterol excreted through the bile by the liver, the amount of which takes 1000 mg. It means that about 1300-1700 mg cholesterol is absorbed in the small intestine daily. Previous major studies have demonstrated that statins, the drugs that have been proved to be the most efficient in decreasing the cholesterol level, can decrease both total and cardiovascular mortality. This effect highly depends on the rate of cholesterol level decrease. Thus, their application in higher doses has been recently suggested to reach the target level, which is performed by dose titration. If the desired effect is not achieved with the starting dose of statins, a doubling of dosage only leads to 6% additional LDL-cholesterol level decrease. During long term administration the so called "escape phenomenon" can be observed, which means that the use of these drugs for a longer period reduces their cholesterol decreasing effect. Higher doses increase the risk of adverse effects, and the "escape phenomenon" decreases the effectiveness. To avoid these effects the combination therapy is recommended for use. In combination therapy drugs with different mechanisms of action should be administered, which increase therapeutic effect, but keep the number of adverse effects decreased or unchanged. Concomitant administration of former known lipid lowering agents - beyond enhancing cholesterol level decrease - has unfortunately increased the frequency of adverse effects as well. In this regard, ezetemibe, the cholesterol absorption inhibitor appears to be promising since it selectively decreases the absorption of cholesterol from intestinal epithelial cell, resulting in an 18-22% LDL-cholesterol decrease. At the same time the decreased uptake from the gastrointestinal tract triggers the endogen cholesterol synthesis in the liver. When this process is inhibited by statin, more impressive cholesterol decreasing effect can be reached. Clinical studies with concurrent use of ezetimibe and statin have confirmed this view. Decreasing cholesterol level at more attack points offers a possibility to reach target values without a significant increase in the risk of adverse effects. So with combination and dual inhibition a more significant cholesterol lowering effect can be obtained beside the decrease of side effects.

KW - Cholesterol

KW - Combination therapy

KW - Ezetimibe

KW - Statin

UR - http://www.scopus.com/inward/record.url?scp=3242727065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242727065&partnerID=8YFLogxK

M3 - Article

C2 - 15188635

AN - SCOPUS:3242727065

VL - 145

SP - 805

EP - 811

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 15

ER -